Le Lézard
Classified in: Health
Subject: FDA

Maxx Orthopedics Announces US FDA Approval of Freedom® Ultra-Congruent Liner Option Ahead of American Academy of Orthopaedic Surgeons (AAOS) Meeting

NORRISTOWN, Pa., March 7, 2019 /PRNewswire-PRWeb/ -- Maxx Orthopedics, Inc. a subsidiary of Maxx Medical, Pvt. Ltd., a rapidly expanding global orthopedics device company, today announced that it has received US FDA clearance for its Freedom® Ultra-Congruent liner, the latest addition to its Freedom Knee® System.

The Freedom® Ultra-Congruent Liner (UC) was developed with the desire to achieve a higher level of constraint than typically achieved in a traditional cruciate-retaining (CR) knee design. The UC tibial liner includes a deep anterior patellar cut-out to allow for tendon clearance, a prominent anterior lip that aids in prevention of anterior subluxation of the femur, and a prominent posterior lip that assists in resisting posterior translation of the femur. Providing patients with more precise balance and stability, the thickness offerings for the Freedom® Ultra-Congruent Liner will be 1mm increments throughout the size range.

"We are thrilled to add the UC liner offering to our Freedom® Knee System. In addition to the unique design of the Ultra-Congruent liner, we are also introducing new liner thicknesses to help our customers better match the Freedom Knee to the needs of the individual patient. This is an evolutionary step towards our goal of creating and providing solutions that best fit our patients' needs so they, along with our medical professionals, continue to have the best possible outcomes." said Ashesh Shah, CEO, Maxx Medical.

Launched in 2009, The Freedom Knee® System is a total knee replacement system specifically engineered for high flexion, bone conservation and advanced component size and fit capabilities. Maxx will be displaying The Freedom® Ultra-Congruent Liner at AAOS Annual Meeting, March 13-15, in Las Vegas, NV (Booth #2063). For additional information, please visit http://www.maxxortho.com.

About Maxx Medical
Maxx Medical Pvt. Ltd. ("Maxx Medical") develops and markets innovative orthopedic medical devices on an international scale. The company is focused on providing state-of-the-art implants and related solutions that best restore patient mobility while accommodating lifestyle, anatomical and economic needs. Maxx Medical is the parent company of Maxx Orthopedics, Inc., the manufacturer of the Freedom Knee® System and Libertas® Total Hip System.


SOURCE Maxx Orthopedics

These press releases may also interest you

at 15:47
For the sixth consecutive year, Astellas has achieved a perfect score on the Human Rights Campaign Foundation's (HRC) annual Corporate Equality Index (the Index). "Fostering a workplace environment that enables respect...

at 15:42
Cell>Point announced today, based on its sponsored chelator and therapeutic research conducted at the University of Texas M.D. Anderson Cancer Center on Platinum-Oncardia and 177Lu-Oncardia, and the positive results of its lung cancer imaging...

at 15:30
Nearly 1.6 billion people worldwide suffer from anemia, and for the first time new research points to how resistance emerges to the drug dexamethasone used to treat the devastating inherited form of anemia known as Diamond Blackfan anemia (DBA). The...

at 15:10
The global diabetes care devices market is expected to reach US$ 39,382.3 Mn in 2027 from US$ 23,354.3 Mn in 2018. The market is estimated to grow with a CAGR of 6.1% from 2019-2027. Read the full report:...

at 15:08
Today, the U.S. Food and Drug Administration (FDA) approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be...

at 15:00
The outbreak of a mysterious new Coronavirus in China and other Asian countries is causing hundreds to fall ill and has travelers questioning if it is safe to visit the affected areas. Travel insurance comparison site, Squaremouth, warns travelers...

News published on 7 march 2019 at 14:00 and distributed by: